Tela Bio Receives FDA Clearance for Liora Monofilament Scaffold

MALVERN, Pa., Oct. 05, 2026 /CourierPR/ -- TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Liora Monofilament Scaffold. This clearance marks a significant milestone for the company as Liora is the first fully resorbable synthetic product in TELA Bio’s portfolio to be designed and produced in-house by the company’s team of engineers.

The Liora Monofilament Scaffold is a fully resorbable surgical mesh device for soft tissue reinforcement, designed to enable TELA Bio to expand its footprint in the soft tissue reconstruction market. This product was developed in TELA Bio's ISO 8 certified cleanroom in Malvern, PA, highlighting the company's commitment to in-house innovation and quality control.

The product is intended to provide surgeons with a new tool to enhance their ability to perform soft tissue reconstructions, potentially leading to better patient outcomes and reduced long-term exposure to permanent synthetic materials.

TELA Bio, Inc. is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response. The Liora Monofilament Scaffold is part of TELA Bio’s broader portfolio, which includes other innovative products designed to support soft tissue repair and reconstruction.

This clearance is subject to the company's ongoing efforts to achieve or sustain profitability and gain market acceptance for its products. TELA Bio remains committed to enhancing its product offerings and maintaining expanded market access, while also addressing potential challenges such as macroeconomic conditions, healthcare economic factors, and product development and manufacturing problems. The company’s commitment to in-house innovation and quality control, as demonstrated by the development of Liora in its ISO 8 certified cleanroom, underscores its dedication to delivering high-quality medical solutions.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.